P. Budde, H.-D. Zucht, S. Konings, L. Steeg, E. Friedrich, C. Gutjahr, R. Steil, S. Bhandari, M. Tuschen, and P. Schulz-Knappe* , EULAR 2018
Conclusions
The Cancer Immunotherapy array is a high-throughput array suitable for the analysis of thousands of cancer patient serum samples. Its first application presents novel autoantibody signatures for therapy-related toxicities (irAEs) as well as response. These signatures have the potential to serve as useful tools that will broaden our understanding of the mechanisms of therapy response and immune-related adverse event (irAE) occurrence.